Compare Organon & Co. Common Stock (OGN) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs iShares Semiconductor ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while iShares Semiconductor ETF trades at $506.11 (market cap $42.65B). The key difference: iShares Semiconductor ETF is far larger — about 11.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and iShares Semiconductor ETF for 47 Days on average.
| OGN | SOXX | |
|---|---|---|
Market Cap | $3.61B | $42.65B |
Volume | 1,808,049 | 10,736,485 |
Sector | Health | Sector/Thematic |
52-Week High | $13.81 | $655.01 |
52-Week Low | $5.70 | $268.10 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SOXX trades at $543.9, down 0.17% with a bearish technical signal. The ETF faces mixed sentiment as AI-driven semiconductor demand fuels optimism, but high valuations and Michael Burry's short positions highlight risks. Recent news shows strong September performance (+11%) and positive earnings revisions, though technical indicators suggest near-term pressure with support at $531.
Outlook hinges on AI infrastructure growth, with BofA projecting the semiconductor market to nearly double by 2030. Risks include valuation concerns (P/E of 68.79 per Seeking Alpha), concentration in top holdings, and macroeconomic volatility. Earnings growth remains a key catalyst, but investors should weigh high multiples against sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
